Core Viewpoint - Investing in stocks priced under $30 can yield significant returns, with Pfizer and Adyen identified as two promising options for investors [2]. Group 1: Pfizer - Pfizer's stock has declined from approximately $60 per share in late 2021 to just under $22, primarily due to reduced sales from its COVID-19 portfolio and upcoming patent cliffs, including Eliquis [3][4]. - Despite recent challenges, Pfizer has developed a robust pipeline, particularly in oncology, which is expected to yield significant clinical and regulatory successes in the near future [4]. - The company has shown resilience in its financial performance, with ongoing contributions from its coronavirus products and a strong dividend yield of 7.8%, appealing to income-focused investors [7][8]. Group 2: Adyen - Adyen, a Netherlands-based fintech, offers integrated payment solutions that are essential for multinational companies, boasting clients like Microsoft, Uber, and Spotify [9]. - The company's stock has experienced volatility due to economic challenges affecting transaction volumes and its decision to maintain spending, which impacted margins [10]. - Adyen's strong customer retention due to switching costs and the ongoing shift to e-commerce present significant growth opportunities, making its shares, priced under $16, an attractive investment [11].